UAB The University of Alabama at Birmingham

The UAB Institutional Biosafety Committee Meeting Minutes
Research Involving Recombinant and Synthetic Nucleic Acid Molecules
October 08, 2026, 9:00 am

Members	Present (Y/N)	Vote (Y/N)
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Aftab Ahmad, PhD, Lab Rep [AA]	N	N
3. Julie Allen, DNP, Occupational Medicine [JSA]	Y	Y
4. Cameron Crosby, MD, Occupational Medicine [JCC]	N	N
5. Qiang (John) Ding, PhD, Veterans' Affairs [QJD]	N	N
6. Chad Dunaway, IACUC [CD]	N	N
7. Lillie Flood, RN-BSN, JCDH, Community Member [LF]	Y	Y
8. Julie Gray, BS, EHS [JDG]	Y	N
9. Kevin Harrod, PhD, Lab Rep [KH]	N	N
10. Rebecca Johnstone, Recording Secretary [RMJ]	Y	N
11. Masakazu Kamata, PhD, Lab Rep [MK]	Y	Y
12. Brian Lagory, BS, Biosafety Officer [BEL]	Y	Y
13. Adam McClintock, MBA, HSR [AM]	N	N
14. Andrea Osborne, DVM, ARP, Animal Expert [AJO]	Y	Y
15. Larisa Pereboeva, PhD, Lab Rep [LP]	N	N
16. Vineel Reddy, PhD, BSO-EHS [VPR]	Y	Y
17. Justin Roth, PhD, EHS [JCR]	N	N
18. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	Y
19. Theresa Strong, PhD, Lab Rep [TVS]	N	N
20. Tyler Uzzell, MA, IRB [TWU]	Y	Y
21. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
22. Wesley Willeford, MD, JCDH, Community Member [WW]	N	N
23. Donna Williamson, MS, RSS [DSW]	N	N
24. Christine M. Wright, PhD, Lab Rep [CMW]	Y	Y
Total	**13**	**11**

Guests Present

Joseph Palmer, PhD, SEBLAB [JP]
Susan Pelmer, RSS [SP]
Laura Caltrider, MS, EHS [LC]
Steven Geisler, JD, University Counsel [SG]
Douglas Fox, PhD, SEBLAB [DMF]
Earle Durboraw, MA, ARP [ED]
Ian Doty, EHS [ID]

The October 08, 2026, Institutional Biosafety Committee (IBC) meeting for research involving recombinant or synthetic nucleic acid molecules was called to order at 9:02 a.m. via web-based video conferencing tool by the Chair. A quorum was present.

Welcome and Introduction of Guests

The Chair welcomed all in attendance.

Presentations

The biosafety manager for SEBLAB gave a presentation on the policies and procedures in place for the upcoming Jingmen virus research.

Approval of September 10, 2026, Minutes

The September 10, 2026, meeting minutes were distributed in the Committee member's packets via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There were two (2) abstentions. The minutes were approved.

Standing Reports

- In the News/Regulatory Visits – There were no updates.
- Faculty Senate – There were no updates.
- Veterans Administration – There were no updates.
- Employee Health – There were no updates.
- ARP/Facilities Operations Report – There were no updates.
- JCDH – There were no updates.
- EHSA – It was reported that development of the bioform and certain reporting functions were ongoing.
- Ongoing Business
  - The current DGOF policy and upcoming NIH regulations were discussed.
- New Business - There were no updates.
- Project Review - The review and discussion of projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.
- Announcements/Discussions – Next meeting date: Thursday, November 12, 2026, 9:00 am

Adjournment

The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 09:57 am.

Respectfully submitted by:



11/04/2026

Rebecca Johnstone — Date

Recording Secretary

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Not Approve	Abstain or Recuse	RSC #	Evaluation
11	--	--	26-170	**(III.C.1) Geisler, William; VAV00023: A Phase 1, randomized, placebo-controlled, multi-arm, study to evaluate the safety of a Chlamydia trachomatis mRNA Vaccine candidate in adults.** **Reason for IBC:** • Administration of mRNA encoding MRT2000, MRT2001, MRT2002, and MRT2003, to one or more human subjects. **Containment Requirements:** • BSL-1 and/or universal precautions will be used for storage, preparation, and administration of the investigational product. • Any unused IP and any potentially contaminated materials will be disposed as medical waste or per the sponsor's instructions. • It should be clearly understood that IBC approval of the project in no way endorses or guarantees the safety of the above recombinant material for administration to humans.
11	--	--	26-158	**(III.C.1) Goepfert, Paul; HVTN 146-A phase 1 clinical trial study to evaluate the safety and immunogenicity of a higher dose of the HCMV-HIV vaccine candidate VIR-1388, in HCMV-seropositive adult participants without HIV** **Reason for IBC:** • Administration of a live, attenuated hCMV vector expressing the HIV-1 Mfuse1 cassette to or more human subjects. **Containment Requirements:** • BSL-2 practices and procedures will be used for preparation of investigational product. • Universal precautions will be used for administration of the investigational product. • Any unused IP and any potentially contaminated materials will be disposed as medical waste or per the sponsor's instructions. • It should be clearly understood that IBC approval of the project in no way endorses or guarantees

				the safety of the above recombinant material for administration to humans.
11	--	--	26-156	**(III.C.1) Wells, James; A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and EVicacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPINA1) Gene in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD)** **Reason for IBC:** • Administration of an investigational product encoding SyNTase-mRNA and tagRNA targeting exon 5 of SERPINA1 to one or more human subjects. **Containment Requirements:** • Universal precautions shall be used for storage, preparation, and administration of the investigational product. • Any potentially contaminated materials shall be disposed as medical waste or per the sponsor's instructions. • It should be clearly understood that IBC approval of the project in no way endorses or guarantees the safety of the above recombinant material for administration to humans.
11	--	--	26-167	**(III.D.1.a) Agarwal, Anupam; Engineering Functional hiPSC-Derived Lymphatic Endothelium to Model Renal Lymphangiogenesis in Acute Kidney Injury** **Reason for IBC:** • Use of replication-incompetent, VSV-G pseudo typed third-generation lentiviral vectors to introduce target genes, reporter constructs, or gene knockdown/knockout elements into cells. **Containment Requirement:** • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with lentivirus and human tissues and cells. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.

11	--	--	26-041	**(III.D.1, III.D.2.a, III.E.1) Davis, Brian; Delivery and Integration of Corrective CFTR Transgenes in Human CF Airway Epithelium** **Reason for IBC:** • Transduction of cell lines with Adeno-associated viral (AAV) vectors or Integrase-Deficient Lentivirus (LV). • Administration of rsNA modified cells to animals **Containment Requirement:** • BSL1 practices and procedures may be used for work with AAV. • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet must be used for any work with human cells and/or LV. • The UAB guidelines for Human Xenograft Experiments in Mice or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable.
11	--	--	26-163	**(III.D.4) Day, Jeremy; Exploiting Orbitofrontal Cortex Enhancer Dynamics in Cocaine Use Disorder for Cell Type-Specific** **Reason for IBC:** • Construction of Adeno-associated viral vectors and lentiviral vectors using human cells for subsequent administration to animals. **Containment Requirements:** • BSL-2 practices and procedures shall be used for all construction of vectors in human cells. • ABSL-2 practices and procedures, including the posting of an AUSI for AAV and LV shall be used for 14 days after the last administration of AAV and LV. Then ABLS-1 will suffice. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.
11	--	--	26-041	**(III.D.3.a) Lu, Qing; Molecular and Cellular Mechanisms and Therapeutic Interventions in Brain Tumorigenesis.** **Reasons for IBC:** • Creation of lentiviral (LV), murine retroviral (RV), and adeno-associated viral (AAV) vectors encoding for tumor suppressors or the knockdown of oncogenes. • Administration of LV, RV, and AAV to animals. • In vitro and in vivo studies with gamma 34.5-deleted oncolytic Herpes Simplex Virus (oHSV) and rsNA CAR-T cells. **Containment Requirements:**

				• BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with LV, oHSV, and/or human cells. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of LV, RV, oHSV, and AAV, then ABSL1 will be used. • An annually certified biosafety cabinet shall be used when handling oHSV-infected animals. • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with oHSV, CAR-T cells. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors. • A Herpes Simplex Virus Exposure Response plan will be made available and reviewed by all working with oHSV.
11	--	--	24-090	**(III.D.1.a, III.D.2.a, III.E.1) Davis, Brian; Delivery and Integration of Corrective CFTR Transgenes in Human CF Airway Epithelium** **Reason for IBC:** • Transduction of cell lines with Adeno-associated viral (AAV) vectors or Integrase-Deficient Lentivirus (LV). • Administration of rsNA modified cells to animals. **Containment Requirements:** • BSL1 practices and procedures may be used for work with AAV. • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet must be used for any work with human cells and/or LV. • The UAB guidelines for Human Xenograft Experiments in Mice or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable.
11	--	--	26-162	**(III.D.4) Galli, Aurelio; Rational Combination Therapy - Synthetic Biology for Exploitation of ROS Generation by Standard-of-Care Therapeutics for Glioblastoma** **Reasons for IBC:** • Administration of rsNA lentiviral vectors to animals. • Creation of rsNA cell lines using lentiviral vectors for subsequent administration to animals. **Containment Requirements:** • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be

				used for all in vitro work with lentivirus and human cell lines. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of lentiviral vectors, then ABSL1 will be used. • The **UAB Guidelines for Conducting Human Xenograft Experiments in Mice** or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.
11	--	--	26-168	**(III.D.2, III.E.1, III.D.4) Nakada, Yuki; Hypoxia induces cardiomyocyte proliferation in mice** **Reasons for IBC:** • In vitro experiments with replication defective rsNA lentiviral vectors in human cells. • Administration of replication defective Adeno-associated viral (AAV) vectors to animals. **Containment Requirements:** • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with LV and human cells. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.
11	--	--	26-171	**(III.D.4) Sun, Xingshen; Ferret Pancreas Lineage Mapping and IPSC-Derived Organoids for Early CF Pathology** **Reasons for IBC:** • Experiments with transgenic animals other than rodents (ferrets). • Use of lentiviral vectors to modify cells, for in vitro work. **Containment Requirements:** • BSL-2 practices and procedures, including the use of an annually certified biosafety cabinet must be used for all work with human cells, lentiviral, vectors, and Sendai vectors. • Standard ferret handling/ABSL1 may be used for procedures with transgenic ferrets.

11	--	--	26-176	**(III.D.4, III.E.1) Hardiman, Karin; Optimizing Response to Chemoradiotherapy in Rectal Cancer Using a Novel Nanotherapy** **Reason for IBC:** • Use of lentiviral (LV) vectors to modify human and mouse cells for subsequent in vitro and in vivo experiments. **Containment Requirements:** • BSL-2 practices and procedures, including the use of an annually certified biosafety cabinet, shall be used for all in work with cell lines and LV. • ABSL-1 practices and procedures may be used for administration of rsNA modified mouse cells to animals. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.
11	--	--	26-174	(III.D.1.b) Lennemann, Nicholas; Establishment of Jingmenvirus Molecular Platforms for Outbreak Preparedness Reason for IBC: • In vitro work with synthetic genomic RNA to enable recovery and work with 3 novel tick-associated Jingmenviruses. Containment Requirements: • BSL-2 practices and procedures may be used for all work prior to virus recovery. • BSL-3 practices and procedures must be used for all work post viral recovery up through neutralization. • An annually certified biosafety cabinet must be used for all work with viruses in this protocol. • The PI is required to actively participate in the development, review, revision, and implementation of all SOPs governing work conducted in SEBLAB, including coordinating with SEBLAB Management and Biosafety and obtaining all necessary approvals before implementing any procedural or equipment changes. • An accurate and timely inventory of viable agent stocks must be maintained using inventory software provided by SEBLAB. • SOPs for spatial and temporal separation of the three viruses are required for this work. • Removal of infectious materials from SEBLAB for downstream analysis requires inactivation using an approved, validated method, with prior review and approval by Biosafety.

				• The SEBLAB Core research team will conduct research activities under BSL-3 containment. If the PI or PI's lab personnel wish to perform BSL-3 activities, SEBLAB training and mentoring will be required for those individuals.